U.S. Markets close in 6 hrs 14 mins

New Healthcare Trends Could Push Sector Stocks Higher

CORAL GABLES, FL / ACCESSWIRE / November 21, 2018 / Healthcare stocks continue to gain traction amid volatile market conditions this week. Investors have been less optimistic on tech stocks and more favorable to the healthcare sector. US midterm elections have also helped to boost a more favorable market for healthcare. The split party control of Congress following means that things like Obamacare aren't going anywhere, and proposals to curtail drug prices are not likely to pass both houses. Healthcare and biotech stocks, after nearly three years of underperformance, have begun to make a comeback during the second half of this year. As a result, the Health Care Sector SPDR (XLV) is rallying vs. the gains for the Dow Jones Industrial Average, returning to the highs seen in the middle of October.

With the latest trends boosting market interest investors are watching healthcare stocks such as Premier Health Group, Inc. (PHGRF) (PHGI), Synthetic Biologics, Inc. (NYSE American: SYN), AcelRx Pharmaceuticals, Inc. (ACRX) and Novelion Therapeutics Inc. (NVLN).

Premier Health Group, Inc. (PHGRF) (PHGI) is focused on developing innovative approaches that combine human skill based expertise with emerging technologies for the healthcare industry. This month, Premier solidified its stance on the increasing opportunity that the legal marijuana industry has presented. Last week Premier Health announced that as a part of its expansion plans, Premier Health will enter the Cannabis clinic space by a series of acquisitions, partnerships and/or launching a new Canada -based chain in the first half of 2019.

"The role of Cannabis in treating medical conditions is continuously expanding. Our doctors have had success treating their patients with various ailments from chronic pain to cancer related symptoms. Unfortunately, there is a gap between the patient's need for medical marijuana, and the family doctor's comfort and knowledge to prescribe it. We are looking to fill that gap with various forms of clinics and services to help our patients and healthcare workers," said Dr. Essam Hamza , Chief Executive Officer of Premier Health.

The Canadian medical cannabis clinic market is estimated to be worth approximately $2.35 billion by 2025. With this in mind, the company said that it expects to provide additional updates on acquisitions in Q4-18 and Q1-19. Shares of Premier Health hit highs of CAD$0.84 on Friday.

For More Information On Premier Health Group, Click Here

Synthetic Biologics, Inc. (SYN) is a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients. Today Synthetic announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss development of SYN-004 (ribaxamase) for the prevention of antibiotic-mediated Clostridium difficile infection (CDI).

Pursuant to the meeting, the FDA has proposed criteria for Phase 3 clinical efficacy and safety, which if achieved, may support submission for marketing approval of ribaxamase on the basis of a single Phase 3 clinical trial. Final agreement on these criteria is contingent on FDA evaluation of a detailed Phase 3 clinical trial protocol.

Synthetic Biologics anticipates initiating the Phase 3 clinical program after securing additional potential financing via a strategic partnership. In parallel, the Company is evaluating opportunities to advance ribaxamase through the pursuit of a more focused clinical indication in a specialty patient population with multiple potential disease endpoints associated with IV beta-lactam-induced gut microbiome damage.

For More Information On Synthetic, Click Here

AcelRx Pharmaceuticals, Inc. (ACRX) continued to climb after its move on Tuesday. AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings. This month the company announced an upcoming presentation at the 17th Annual Pain Medicine Meeting of the American Society of Regional Anesthesia and Pain Medicine (ASRA). The presentation is part of the Emerging Technology Moderated Poster session.

The Company has one approved product in the U.S., DSUVIA (sufentanil sublingual tablet, 30 mcg), known as DZUVEO in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe.

For More Information On AcelRX, Click Here

Novelion Therapeutics Inc. (NVLN) is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. Novelion has a rare disease product portfolio through its subsidiary, Aegerion Pharmaceuticals, Inc.

The company announced an upcoming presentation at the 17th Annual Pain Medicine Meeting of the American Society of Regional Anesthesia and Pain Medicine (ASRA). The presentation is part of the Emerging Technology Moderated Poster session

In addition, the company reported financial results for the third quarter and nine months ended September 30, 2018. In a separate press release on November 8, 2018, this month. Novelion's Chief Financial Officer Michael Price commented, "In the third quarter we saw a positive impact from the cost reduction initiatives that we implemented throughout 2018, reflecting significant improvements in our operating expenses and bottom line, with GAAP net loss improving by approximately 50% and non-GAAP net loss improving by approximately 79% when compared to the same period in 2017. Additionally, we are pleased that our operating subsidiary, Aegerion Pharmaceuticals, Inc. ("Aegerion"), was able to secure the bridge financing that we announced yesterday, which we believe positions Aegerion to achieve a more comprehensive capital restructuring - our primary near-term goal."

For More Information On Novelion, Click Here

What Is Stock Price (StockPrice.com)?

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.

StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid "500,000" shares of restricted common shares. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.

Contact Information:


SOURCE: StockPrice.com